Cystic Fibrosis Research
Cystic fibrosis (CF) is a common inherited disease that mostly affects the lungs and airways of a sufferer. One of the main pathological characteristics of CF is the failure of airway defence against bacterial infection, leading to frequent chest infection and progressive lung damage.
Cystic Fibrosis Research Products Targets
Products for Cystic Fibrosis Research - Page 8
- Cat.No. Product Name Information/Activity
-
BCC7310
FPL 55712
40785-97-5
-
BCC7334
MK 571
MRP1 inhibitor; also CysLT<sub>1</sub> (LTD<sub>4</sub>) inverse agonist
-
BCC4680
Montelukast Sodium
Montelukast (sodium) (MK0476) is a potent, selective CysLT1 receptor antagonist.
-
BCC4827
Pranlukast
Pranlukast is a highly potent, selective and competitive antagonist of peptide leukotrienes. Pranlukast inhibits [3H]LTE4, [3H]LTD4, and [3H]LTC4 bindings to lung membranes with Kis of 0.63±0.11, 0.99±0.19, and 5640±680 nM, respectively.
-
BCC7180
SR 2640 hydrochloride
146662-42-2
-
BCC6274
Gue 1654
397290-30-1
-
BCN2215
Arachidonic acid
Arachidonic acid is an essential fatty acid and a major constituent of biomembranes.
-
BCC6038
BAY-X 1005
Veliflapon (BAY X 1005; DG-031) is an orally active and selective 5-lipoxygenase activating protein (FLAP) inhibitor. Veliflapon inhibits the synthesis of the leukotrienes B4 and C4.
-
BCC7457
Cilastatin sodium
81129-83-1
-
BCC7017
MK 886
MK886 is a potent 5-lipoxygenase activating protein inhibitor (FLAP) also a non-competitive inhibitor of PPAR alpha. a potent inhibitor of leukotriene (LT) biosynthesis in intact human polymorphonuclear leukocytes with IC 50 of 2.5 nM. Block the synthessis of leukotrien intact activate leukocyte.
